236 related articles for article (PubMed ID: 11884652)
21. Is quality of life in non-demented Parkinson's disease patients related to cognitive performance? A clinic-based cross-sectional study.
Klepac N; Trkulja V; Relja M; Babić T
Eur J Neurol; 2008 Feb; 15(2):128-33. PubMed ID: 18217883
[TBL] [Abstract][Full Text] [Related]
22. Psychiatric symptoms screening in the early stages of Parkinson's disease.
Bugalho P; da Silva JA; Cargaleiro I; Serra M; Neto B
J Neurol; 2012 Jan; 259(1):124-31. PubMed ID: 21691730
[TBL] [Abstract][Full Text] [Related]
23. Neuropsychological impairments associated with severity of Parkinson's disease.
Huber SJ; Freidenberg DL; Shuttleworth EC; Paulson GW; Christy JA
J Neuropsychiatry Clin Neurosci; 1989; 1(2):154-8. PubMed ID: 2521056
[TBL] [Abstract][Full Text] [Related]
24. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole.
Lemke MR; Brecht HM; Koester J; Kraus PH; Reichmann H
J Neuropsychiatry Clin Neurosci; 2005; 17(2):214-20. PubMed ID: 15939976
[TBL] [Abstract][Full Text] [Related]
25. Hedonic tone and its mood and cognitive correlates in Parkinson's disease.
Spalletta G; Fagioli S; Meco G; Pierantozzi M; Stefani A; Pisani V; Caltagirone C; Pontieri FE; Assogna F
Depress Anxiety; 2013 Jan; 30(1):85-91. PubMed ID: 23300113
[TBL] [Abstract][Full Text] [Related]
26. Predictors of performance-based measures of instrumental activities of daily living in nondemented patients with Parkinson's disease.
Pirogovsky E; Martinez-Hannon M; Schiehser DM; Lessig SL; Song DD; Litvan I; Filoteo JV
J Clin Exp Neuropsychol; 2013; 35(9):926-33. PubMed ID: 24074137
[TBL] [Abstract][Full Text] [Related]
27. Performance of Greek demented and nondemented subjects on the Greek version of the Mattis Dementia Rating Scale. A validation study.
Katsarou Z; Bostantjopoulou S; Zikouli A; Kazazi E; Kafantari A; Tsipropoulou V; Kourtesi G; Peitsidou E
Int J Neurosci; 2010 Nov; 120(11):724-30. PubMed ID: 20942587
[TBL] [Abstract][Full Text] [Related]
28. Apathy may herald cognitive decline and dementia in Parkinson's disease.
Dujardin K; Sockeel P; Delliaux M; Destée A; Defebvre L
Mov Disord; 2009 Dec; 24(16):2391-7. PubMed ID: 19908317
[TBL] [Abstract][Full Text] [Related]
29. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
Smith KM; Eyal E; Weintraub D;
JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
[TBL] [Abstract][Full Text] [Related]
30. A registry-based, case-control investigation of Parkinson's disease with and without cognitive impairment.
Papapetropoulos S; Ellul J; Polychronopoulos P; Chroni E
Eur J Neurol; 2004 May; 11(5):347-51. PubMed ID: 15142230
[TBL] [Abstract][Full Text] [Related]
31. [Depressive pseudodementia in early Parkinson's disease: lessons from a case with long-term follow-up].
Giménez-Roldán S; Mateo D; Dobato JL
Neurologia; 1997 Mar; 12(3):130-5. PubMed ID: 9198454
[TBL] [Abstract][Full Text] [Related]
32. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group.
Growdon JH; Kieburtz K; McDermott MP; Panisset M; Friedman JH
Neurology; 1998 May; 50(5):1327-31. PubMed ID: 9595982
[TBL] [Abstract][Full Text] [Related]
33. Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study).
Reid WG; Hely MA; Morris JG; Loy C; Halliday GM
J Neurol Neurosurg Psychiatry; 2011 Sep; 82(9):1033-7. PubMed ID: 21335570
[TBL] [Abstract][Full Text] [Related]
34. Lateralized neuropsychological functioning in depressive patients before and after drug therapy.
de Groot MH; Nolen WA; Huijsman AM; Bouvy PF
Biol Psychiatry; 1996 Dec; 40(12):1282-7. PubMed ID: 8959293
[TBL] [Abstract][Full Text] [Related]
35. Long-term cognitive follow-up of Parkinson's disease patients with impulse control disorders.
Siri C; Cilia R; Reali E; Pozzi B; Cereda E; Colombo A; Meucci N; Canesi M; Zecchinelli AL; Tesei S; Mariani CB; Sacilotto G; Zini M; Pezzoli G
Mov Disord; 2015 Apr; 30(5):696-704. PubMed ID: 25757654
[TBL] [Abstract][Full Text] [Related]
36. [The effect of amantadine sulfate on cognitive disorders in patients with Parkinson's disease].
Iablonskaia AIu; Fedorova NV; Bel'gusheva ME
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(7):24-30. PubMed ID: 20639853
[TBL] [Abstract][Full Text] [Related]
37. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia.
Barton B; Grabli D; Bernard B; Czernecki V; Goldman JG; Stebbins G; Dubois B; Goetz CG
Mov Disord; 2012 Feb; 27(2):248-53. PubMed ID: 22162144
[TBL] [Abstract][Full Text] [Related]
38. The independent influence of apathy and depression on cognitive functioning in Parkinson's disease.
Butterfield LC; Cimino CR; Oelke LE; Hauser RA; Sanchez-Ramos J
Neuropsychology; 2010 Nov; 24(6):721-30. PubMed ID: 20853956
[TBL] [Abstract][Full Text] [Related]
39. Cognitive impairments and depression in Parkinson's disease.
Madeley P; Biggins CA; Boyd JL; Mindham RH
J Neurol Neurosurg Psychiatry; 1991 Oct; 54(10):941. PubMed ID: 1744661
[No Abstract] [Full Text] [Related]
40. Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies.
Wesnes KA; Aarsland D; Ballard C; Londos E
Int J Geriatr Psychiatry; 2015 Jan; 30(1):46-54. PubMed ID: 24737460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
